<DOC>
	<DOCNO>NCT01574820</DOCNO>
	<brief_summary>Objectives : The investigator examine whether rosiglitazone , thiazolidinedione ( TZD ) , beneficial pre-diabetes mellitus ( DM ) adult document coronary artery disease ( CAD ) . Background : Microvascular macrovascular complication common type 2 DM . There evidence effect TZDs , synthetic peroxisome proliferator-activated receptor ( PPAR ) -Î³ activator ( insulin sensitizer adipose transcriptional regulation anti-inflammatory process activator ) pre-DM patient document CAD .</brief_summary>
	<brief_title>Role Rosiglitazone Pre-Diabetes Mellitus Coronary Artery Disease</brief_title>
	<detailed_description>Materials Methods : This randomize , double-blind , placebo-controlled study , patient randomly assign TZD group placebo group 6-month treatment period . Biomarkers also examine 6 month post-treatment trial . The primary end-points diagnosis major cardiovascular event : myocardial infarction , overt heart failure , surgery coronary intervention CAD .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>document CAD angiography insulin resistance glucose intolerance 18 80 year age DM treatment allergy TZD active inflammation chronic disease NSAID treatment active heart failure unwilling unable sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>prediabetes</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>glucose intolerance</keyword>
</DOC>